digital therapeutics

By Dave Muoio January 4, 2018
An analysis contracted by WellDoc found that the company’s digital therapeutic for Type 2 diabetes management could lead to an average savings of more than $250 per patient per month. “The cost of a well-controlled diabetes patient will typically range in the $13,000 range [to] $20,000 annually. When you contrast that with the cost of a patient that doesn’t have diabetes, that number is typically...
By Dave Muoio January 2, 2018
Boston- and San Francisco-based Pear Therapeutics, maker of a prescription digital therapeutic platform, announced today the closure of $50 million in Series B funding. The round was led by Singapore-based investment company Temasek, with participation from returning investors 5AM Ventures, Arboretum Ventures, and JAZZ Venture Partners, as well as new partners Novartis, EDBI, and the Bridge...
By Dave Muoio December 4, 2017
Boston-based Akili Interactive Labs has announced positive results from the largest clinical trial of its video game-based pediatric ADHD treatment yet. In light of these data, the company announced that it now plans to file AKL-T01, also known as Project: Evo ADHD Treatment, for FDA clearance as a novel treatment for children and adolescents with ADHD “This is, any way you slice it, our largest...
By Jonah Comstock October 25, 2017
A group of  health startups in the burgeoning digital therapeutics space have joined together to create a new industry association, the Digital Therapeutics Alliance (DTA). “Digital therapeutics are re-writing our definition of medicine,” Akili Interactive CEO Eddie Martucci said in a statement. “It’s critical that industry, academia, government, and the medical community work together in the...
By Jonah Comstock September 14, 2017
In an FDA first, Boston- and San Francisco-based Pear Therapeutics' reSET system for the treatment of substance abuse has been granted a de novo clearance by the agency. It's the first software-only digital therapeutic the FDA has cleared with claims to improve clinical outcomes in a disease. “This is a defining moment for digital therapeutics and for patients with substance use disorder,” Corey...
By Skip Fleshman February 16, 2017
About the author: Skip Fleshman is a partner at Asset Management Ventures who has invested in companies such as Proteus Digital Health, WellDoc, HealthTap, Evidation Health, Reify Health, Lark and Welkin. You can follow him on Twitter @skipfleshman and @amv. Digital health technologies will transform healthcare. Mobile phones have given health care providers the ability to engage with patients 24...
By Jonah Comstock June 13, 2016
Digital health and digital therapeutics will produce a tremendous amount of data, which could be the key to getting them reimbursed by payers, according to panelists at BIO 2016 last week. UCSF Professor of Health Economics and Health Services Research Kathryn Phillips led a panel that included Rowan Chapman, managing director of new business ventures at GE Ventures; Evidation Health CEO Deborah...